Endothelial Progenitor cells in sprouting angiogenesis: Proteases pave the way

Current Molecular Medicine

Volumn 15, Issue 7, 2015, Pages 606-620

  Laurenzana, A ^a   Fibbi, G ^a   Margheri, F ^a   Biagioni, A ^a   Luciani, C ^a   Del Rosso, M ^a   Chilla A ^a  

^a Department of Experimental   (Italy)

Author keywords

Angiogenesis; Cathepsins; Endothelial progenitor cells (EPCs); Matrix metalloproteinases (MMPs); Proteases; UPA uPAR

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; BLOOD CLOTTING FACTOR 12; CD146 ANTIGEN; CD31 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNINDEXED DRUG; UROKINASE; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 3; VON WILLEBRAND FACTOR; UROKINASE RECEPTOR;

ANGIOGENESIS; ARTICLE; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; DOWN REGULATION; EMBRYO DEVELOPMENT; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL PROGENITOR CELL; EXTRACELLULAR MATRIX; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; UPREGULATION; ANIMAL; CELL DIFFERENTIATION; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; CELL DIFFERENTIATION; ENDOTHELIAL PROGENITOR CELLS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84942113438     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150831131214     Document Type: Article

References (152)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
2. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumor-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3: 411-21.
3. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumor endothelium. Nature 2010; 468: 829-33.
4. Leenders WP, Kusters B, de Waal RM. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002; 9: 83-7.
5. Kucera T, Lammert E. Ancestral vascular tube formation and its adoption by tumors. Biol Chem 2009; 390: 985-94.
6. Shi Q, Rafii S, Wu MH, Wijelath ES, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-7.
7. Liu J, Huang J, Yao WY, et al. The origins of vascularization in tumors. Front Biosci 2012; 17: 2559-65.
8. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-201.
9. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for antiangiogenesis therapy? Nat Rev Cancer 2002; 2: 826-35.
10. Verloop RE, Koolwijk P, van Zonneveld AJ, van Hinsbergh VW. Proteases and receptors in the recruitment of endothelial progenitor cells in neovascularization. Eur Cytokine Netw 2009; 20: 207-19.
11. de la Puente P, Muz B, Azab F, Azab AK. Cell trafficking of endothelial progenitor cells in tumor progression. Clin Cancer Res 2013; 19: 3360-8.
12. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013; 2013: 928315.
13. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-78.
14. Van Hinsbergh VWM, Engelse MA, Quax PHA. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 716-28.
15. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
16. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001; 86: 346-55.
17. Remacle AG, Rozanov DV, Day R, Strongin AY. Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene 2006; 25: 5648-55.
18. Mori H, Tomari T, Koshikawa N, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 2002; 21: 3949-59.
19. Kudo T, Takino T, Miyamori H, Thompson EW, Sato H. Substrate choice of membrane-type 1 matrix metalloproteinase is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci 2007; 98: 563-8.
20. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-93.
21. Brooks PC, Silletti S, von Schalscha TL, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400.
22. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin alpha v beta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001; 98: 119-24.
23. Montuori N, Ragno P. Role of uPA/uPAR in the modulation of angiogenesis. Chem Immunol Allergy 2014; 99: 105-22.
24. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002; 67: 92-8.
25. Goretzki L, Schmitt M, Mann K, et al. Effective activation of the proenzyme form of the urokinase-type plasminogen activator [pro-uPA] by the cysteine protease cathepsin L. FEBS Lett 1992; 297: 112-8.
26. Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptorbound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 1991; 266: 5147-52.
27. Del Rosso M, Margheri F, Serrati S, et al. The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Curr Pharm Des 2011; 17: 1924-43.
28. Hoyer-Hansen G, Ronne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224-9.
29. Ploug M, Ronne E, Behrendt N, et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 1991; 266: 1926-33.
30. Miles LA, Levin EG, Plescia J, Collen D, Plow EF. Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. Blood 1988; 72: 628-35.
31. Plow EF, Doeuvre L, Das R. So many plasminogen receptors: why? J Biomed Biotechnol 2012; 2012: 141806.
32. Deryugina E, Quigley JP. Cell surface remodeling by plasmin: a new function for an old enzyme J Biomed Biotechnol 2012; 2012: 564259.
33. Del Rosso M, Fibbi G, Pucci M, et al. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 2002; 19: 193-207.
34. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-43.
35. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci [Landmark Ed] 2009; 14: 4575-87.
36. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010; 584: 1923-30.
37. Sidenius N, Blasi F. Domain 1 of the urokinase receptor [uPAR] is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 2000; 470: 40-6.
38. Eden G, Archinti M, Furlan F, et al. The urokinase receptor interactome. Curr Pharm Des 2011; 17: 1874-89.
39. Stoppelli MP, Tacchetti C, Cubellis MV, et al. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45: 675-84.
40. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des 2003; 9: 1565-74.
41. Stephens RW, Pollanen J, Tapiovaara H, et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-9.
42. Prager GW, Breuss JM, Steurer S, et al. Vascular endothelial growth factor [VEGF] induces rapid prourokinase [pro-uPA] activation on the surface of endothelial cells. Blood 2004; 103: 955-62.
43. Frittoli E, Palamidessi A, Disanza A, et al. Secretory and endo/exocytic trafficking in invadopodia formation: the MT1-MMP paradigm. Eur J Cell Biol 2011; 90: 108-14.
44. Brunner PM, Heier PC, Mihaly-Bison J, et al. Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells. Blood 2011; 117: 4154-61.
45. Del Rosso M. uPAR in angiogenesis regulation. Blood 2011; 117: 3941-3.
46. Poettler M, Unseld M, Mihaly-Bison J, et al. The urokinase receptor [CD87] represents a central mediator of growth factor-induced endothelial cell migration. Thromb Haemost 2012; 108: 357-66.
47. Alexander RA, Prager GW, Mihaly-Bison J, et al. VEGFinduced endothelial cell migration requires urokinase receptor [uPAR]-dependent integrin redistribution. Cardiovasc Res 2012; 94: 125-3.
48. Schmaier AH, Larusch G. Factor XII: new life for an old protein. Thromb Haemost 2010; 104: 915-18.
49. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007; 26: 587-96.
50. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-8.
51. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777-84.
52. Haas TL, Milkiewicz M, Davis SJ, et al. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 2000; 279: H1540-7.
53. Chun TH, Sabeh F, Ota I, et al. MT1-MMP-dependent neovessel formation within the confines of the threedimensional extracellular matrix. J Cell Biol 2004; 167: 757-67.
54. Senger DR, Davis GE. Angiogenesis. Cold Spring Harbor Perspect Biol 2011; 3: a005090.
55. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998; 125: 725-32.
56. Bailey AS, Fleming WH. Converging roads: evidence for an adult hemangioblast. Exp Hematol 2003; 31: 987-93.
57. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-7.
58. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
59. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-60.
60. Yoon CH, Hur J, Park KW, et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005; 112: 1618-27.
61. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-9.
62. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51: 660-8.
63. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1584-95.
64. Piaggio G, Rosti V, Corselli M, et al. Endothelial colonyforming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood 2009; 114: 3127-30.
65. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 2003; 90: 570-6.
66. Eilken HM, Adams RH. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol 2010; 22: 617-25.
67. Risau W, Sariola H, Zerwes HG, et al. Vasculogenesis and angiogenesis in embryonic stem cell derived embryoid bodies. Development 1988; 102: 471-8.
68. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
69. Zhan K, Bai L, Xu J. Role of vascular endothelial progenitor cells in construction of new vascular loop. Microvasc Res 2013; 90: 1-11.
70. Gao D, Nolan D, McDonnell K, et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009; 1796: 33-40.
71. Gao D, Nolan DJ, Mellick AS, et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008; 319: 195-8.
72. Nolan DJ, Ciarrocchi A, Mellick AS, et al. Bone marrowderived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Develop 2007; 21: 1546-58.
73. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-6.
74. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-53.
75. Urbich C, Heeschen C, Aicher A, et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-16.
76. Ruzinova MB, Schoer RA, Gerald W, et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003; 4: 277-89.
77. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11: 261-2.
78. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9.
79. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-6.
80. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-96.
81. Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension 2005; 45: 321-5.
82. Iwakura A, Luedemann C, Shastry S, et al. Estrogenmediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003; 108: 3115-21.
83. Arroyo AG, Taverna D, Whittaker CA, et al. In vivo roles of integrins during leukocyte development and traffic: insights from the analysis of mice chimeric for alpha 5, alpha v, and alpha 4 integrins. J Immunol 2000; 165: 4667-75.
84. Arroyo AG, Yang JT, Rayburn H, Hynes RO. Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity 1999; 11: 555-66.
85. Vermeulen M, Le Pesteur F, Gagnerault MC, et al. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood 1998; 92: 894-900.
86. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 [CD106] is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-97.
87. Levesque JP, Hendy J, Takamatsu Y, et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002; 30: 440-9.
88. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010; 62: 726-59.
89. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992; 359: 843-5.
90. Barthelmes D, Irhimeh MR, Gillies MC, Zhu L, Shen W. Isolation and characterization of mouse bone marrow-derived Lin-/VEGF-R2+ progenitor cells. Ann Hematol 2013; 92: 1461-72.
91. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-37.
92. Topol EJ. Current status and future prospects for acute myocardial infarction therapy. Circulation 2003; 108(16 Suppl 1): 1116-3.
93. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-9.
94. Brenner W, Aicher A, Eckey T, et al. 111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med 2004; 45: 512-8.
95. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
96. Capoccia BJ, Shepherd RM, Link DC. G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 2006; 108: 2438-45.
97. Jujo K, Hamada H, Iwakura A, et al. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci USA 2010; 107: 11008-13.
98. Yao JS, Chen Y, Zhai W, et al. Minocycline exerts multiple inhibitory effects on vascular endothelial growth factorinduced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res 2004; 95: 364-71.
99. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, et al. Upregulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 2003; 171: 4340-51.
100. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-21.
101. Wu Y, Dai J, Schmuckler NG, et al. Cleaved high molecular weight kininogen inhibits tube formation of endothelial progenitor cells via suppression of matrix metalloproteinase 2. J Thromb Haemost 2010; 8: 185-93.
102. Huang PH, Chen YH, Wang CH, et al. Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009; 29: 1179-84.
103. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737-44.
104. Morancho A, Hernandez-Guillamon M, Boada C, et al. Cerebral ischaemia and matrix metalloproteinase-9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells. J Cell Mol Med 2013; 17: 1543-53.
105. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxiainduced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007; 27: 2664-70.
106. Dong L, Kang L, Ding L, et al. Insulin modulates ischemiainduced endothelial progenitor cell mobilization and neovascularization in diabetic mice. Microvasc Res 2011; 82: 227-36.
107. Silvestre JS, Levy BI. Molecular basis of angiopathy in diabetes mellitus. Circ Res 2006; 98: 4-6.
108. Iwakura A, Shastry S, Luedemann C, et al. Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 2006; 113: 1605-14.
109. Suriano R, Chaudhuri D, Johnson RS, et al. 17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. Cancer Res 2008; 68: 6038-42.
110. Chakroborty D, Chowdhury UR, Sarkar C, et al. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 2008; 118: 1380-9.
111. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-20.
112. Cheng XW, Kuzuya M, Nakamura K, et al. Mechanisms underlying the impairment of ischemia-induced neovascularization in matrix metalloproteinase 2-deficient mice. Circ Res 2007; 100: 904-13.
113. Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004; 95: 930-5.
114. Vagima Y, Avigdor A, Goichberg P, et al. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J Clin Invest 2009; 119: 492-503.
115. De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004; 104: 3472-82.
116. Kocher AA, Schuster MD, Bonaros N, et al. Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines. J Mol Cell Cardiol 2006; 40: 455-64.
117. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 2005; 102: 18111-6.
118. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Develop 2008; 22: 559-74.
119. Di Santo S, Diehm N, Ortmann J, et al. Oxidized low density lipoprotein impairs endothelial progenitor cell function by downregulation of E-selectin and integrin alpha[v]beta5. Biochem Biophys Res Commun 2008; 373: 528-32.
120. Carmona G, Chavakis E, Koehl U, Zeiher AM, Dimmeler S. Activation of Epac stimulates integrin-dependent homing of progenitor cells. Blood 2008; 111: 2640-6.
121. Dai X, Tan Y, Cai S, et al. The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells. J Cell Mol Med 2011; 15: 1299-309.
122. Caiado F, Dias S. Endothelial progenitor cells and integrins: adhesive needs. Fibrogenesis Tissue Repair 2012; 5: 4.
123. Chavakis E, Hain A, Vinci M, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007; 100: 204-12.
124. Kamei M, Brian SW, Bayless KJ, et al. Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 2006; 442: 453-6.
125. Bayless KJ, Davis GE. The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. J Cell Sci 2002; 115: 1123-36.
126. Saunders WB, Bohnsack BL, Faske JB, et al. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 2006; 175: 179-91.
127. Hanjaya-Putra D, Yee J, Ceci D, et al. Vascular endothelial growth factor and substrate mechanics regulate in vitro tubulogenesis of endothelial progenitor cells. J Cell Mol Med 2010; 14: 2436-47.
128. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
129. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-76.
130. Zucker S, Mirza H, Conner CE, et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of pro-thrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998; 75: 780.
131. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B [MMP-9] by gelatinase A [MMP-2]. Cancer Res 1995; 55: 2548-55.
132. Han YP, Tuan TL, Hughes M, Wu H, Garner WL. Transforming growth factor-beta -and tumor necrosis factoralpha-mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem 2001; 276: 22341-50.
133. Han JK, Kim HL, Jeon KH, et al. Peroxisome proliferatoractivated receptor-δ activates endothelial progenitor cells to induce angio-myogenesis through matrix metallo-proteinase-9-mediated insulin-like growth factor-1 paracrine networks. Eur Heart J 2013; 34: 1755-65.
134. Maeng YS, Choi HJ, Kwon JY, et al. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCbeta2 axis. Blood 2009; 113: 233-43.
135. Basire A, Sabatier F, Ravet S, et al. High urokinase expression contributes to the angiogenic properties of endothelial cells derived from circulating progenitors. Thromb Haemost 2006; 95: 678-88.
136. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
137. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 1926-33.
138. Sitrin RG, Johnson DR, Pan PM, et al. Lipid raft compartmentalization of urokinase receptor signaling in human neutrophils. Am J Resp Cell Mol Biol 2004; 30: 233-41.
139. Margheri F, Chilla A, Laurenzana A, et al. Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae. Blood 2011; 118: 3743-55.
140. Gardsvoll H, Gilquin B, Le Du MH, et al. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. J Biol Chem 2006; 281: 19260-72.
141. Margheri F, Luciani C, Taddei ML, et al. The receptor for urokinase-plasminogen activator [uPAR] controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget 2014; 5: 1538-53.
142. Laurenzana A, Biagioni A, D'Alessio S, et al. Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. Oncotarget 2014; 5: 3711-27.
143. Margheri F, Papucci L, Schiavone N, et al. Differential uPAR recruitment in caveolar-lipid rafts by GM1 and GM3 gangliosides regulates endothelial progenitor cells angiogenesis. J Cell Mol Med 2015; 19: 113-23.
144. Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood 2007; 110: 2432-9.
145. Urbich C, Heeschen C, Aicher A, et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005; 11: 206-13.
146. Ricard-Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Exp Dermatol 2014; 23: 457-63.
147. Monboisse JC, Oudart JB, Ramont L, Brassart-Pasco S, Maquart FX. Matrikines from basement membrane collagens: a new anti-cancer strategy. Biochim Biophys Acta 2014; 1840: 2589-98.
148. Dome B, Timar J, Ladanyi A, et al. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Crit Rev Oncol Hematol 2009; 69: 108-24.
149. Nienartowicz A, Sobaniec-Lotowska ME, Jarocka-Cyrta E, Lemancewicz D. Mast cells in neoangiogenesis. Med Sci Monit 2006; 12: RA53-6.
150. Sica A, Schioppa T, Mantovani A, Allavena P. Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-27.
151. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117: 1155-66.
152. Hur J, Yang HM, Yoon CH, et al. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation 2007; 116: 1671-82.